logo
Share SHARE
FONT-SIZE Plus   Neg

Pfizer's Rheumatoid Arthritis Drug Xeljanz Gets Approval In Japan

Pharmaceutical giant Pfizer Inc. (PFE) Monday said the Japanese Ministry of Health, Labor and Welfare has approved Xeljanz for the treatment of adults with rheumatoid arthritis or RA who have had an inadequate response to existing therapies. The company added saying the drug may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug, such as methotrexate.

Xeljanz is expected to be initially made available in Japan to medical institutions participating in an all-patient surveillance program. The drug will be commercially available in Japan after the National Health Insurance listing and will be co-promoted in Japan by Pfizer and Takeda Pharmaceutical Company Limited.

The approval of Xeljanz in Japan is supported by a multi-study, global clinical development program, which evaluated the drug in approximately 5,000 patients across various RA patient populations.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
France-based optical-lens maker Essilor International SA (EL), Delfin and Ray-Ban maker Luxottica Group (LUX) Monday announced their plan to merge in a deal valued around $49 billion. Essilor would become a holding company with the new name "EssilorLuxottic." Uncertainty has become the name of the game, as the new president is set to assume office. Groundwork is being done for major policy overhauls, with the first step towards repealing the Obamacare taken, as Senators voted 51-48 to approve a budget resolution for achieving the same. The House is set to... A country's productivity is measured by dividing its gross domestic product or GDP in U.S. dollars and normalized to purchasing power parities by the total number of hours worked by the country's workforce in a year. It is considered as a key driver of long-term economic growth and living standards. CLICK...
comments powered by Disqus
Follow RTT